BSE Live
Jun 02, 16:01Prev. Close
639.75
Open Price
641.80
Bid Price (Qty.)
632.95 (1)
Offer Price (Qty.)
641.50 (23)
NSE Live
Jun 02, 15:47Prev. Close
640.55
Open Price
634.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Eris Lifesciences (in Rs. Cr.) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 1,307.12 | 1,193.77 | 1,088.65 | 1,003.76 | 881.13 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 1,307.12 | 1,193.77 | 1,088.65 | 1,003.76 | 881.13 | |
Total Operating Revenues | 1,330.73 | 1,215.73 | 1,108.83 | 1,020.23 | 896.54 | |
Other Income | 17.26 | 28.99 | 10.00 | 14.73 | 32.50 | |
Total Revenue | 1,347.99 | 1,244.72 | 1,118.83 | 1,034.96 | 929.04 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 114.13 | 117.57 | 99.43 | 76.88 | 58.19 | |
Purchase Of Stock-In Trade | 113.76 | 79.59 | 111.65 | 70.00 | 87.56 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | 8.50 | 2.49 | -12.57 | 17.47 | -13.40 | |
Employee Benefit Expenses | 252.52 | 222.18 | 207.02 | 191.73 | 166.77 | |
Finance Costs | 20.81 | 2.99 | 0.78 | 1.85 | 22.79 | |
Depreciation And Amortisation Expenses | 64.66 | 51.46 | 37.64 | 44.88 | 31.59 | |
Other Expenses | 336.71 | 309.90 | 285.99 | 308.54 | 263.76 | |
Total Expenses | 911.08 | 786.18 | 729.94 | 711.37 | 617.26 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 436.91 | 458.54 | 388.89 | 323.59 | 311.78 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 436.91 | 458.54 | 388.89 | 323.59 | 311.78 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 38.90 | 80.17 | 70.18 | 57.49 | 68.87 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | 0.00 | -38.83 | -31.90 | -25.17 | -42.47 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 38.90 | 41.35 | 38.29 | 32.32 | 26.40 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 398.01 | 417.19 | 350.61 | 291.27 | 285.38 | |
Profit/Loss From Continuing Operations | 398.01 | 417.19 | 350.61 | 291.27 | 285.38 | |
Profit/Loss For The Period | 398.01 | 417.19 | 350.61 | 291.27 | 285.38 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 29.27 | 30.70 | 25.82 | 21.23 | 20.75 | |
Diluted EPS (Rs.) | 29.23 | 30.70 | 25.80 | 21.21 | 20.74 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 0.00 | 81.65 | 74.68 | 38.97 | 0.00 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 8.01 | 0.00 | |
Equity Dividend Rate (%) | 735.00 | 601.00 | 550.00 | 287.00 | 0.00 |
17.05.2023
Eris Life Standalone March 2023 Net Sales at Rs 314.58 crore, up 11.5% Y-o-Y
17.05.2023
Eris Life Consolidated March 2023 Net Sales at Rs 402.80 crore, up 31.66% Y-o-Y
20.01.2023
Eris Life Consolidated December 2022 Net Sales at Rs 423.26 crore, up 27.43% Y-o-Y
20.01.2023
Eris Life Standalone December 2022 Net Sales at Rs 332.01 crore, up 8.99% Y-o-Y
17.01.2023
Eris Lifesciences Q3 PAT seen up 7.2% YoY to Rs 1,080 cr: Nirmal Bang
08.07.2022
Eris Lifesciences Q1 PAT seen up 4.3% YoY to Rs 111.3 cr: Prabhudas Lilladher
14.04.2022
Eris Lifesciences Q4 PAT seen up 30.7% YoY to Rs 89.2 cr: Prabhudas Lilladher
13.01.2022
Eris Lifesciences Q3 PAT seen up 12.4% YoY to Rs 101.4 cr: Prabhudas Lilladher